What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
Focused on rare skin disease therapies, this clinical-stage biotech just reported a notable insider sale amid a year of sharp stock gains.
Overview
Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (NASDAQ:PVLA), reported the exercise of 4,302 stock options immediately converted and sold as common shares for a transaction value of approximately $476,000 according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($110.73).
Details
Palvella Therapeutics is a biotechnology company focused on advancing innovative therapies for rare and severe skin diseases. With a lean operational structure and a pipeline centered on QTORIN rapamycin, the company leverages clinical research to address unmet medical needs in dermatology. Its strategic emphasis on orphan indications and mTOR pathway diseases positions Palvella to compete in specialized markets where few alternatives exist.
Source
Originally published at www.fool.com.